Release Date: 23-Jan-2025
Sabestomig (AZD7789) is a bispecific monoclonal antibody developed by AstraZeneca, designed to target two key immune checkpoints, programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin domain 3 (TIM-3). Both PD-1 and TIM-3 play significant roles in regulating anti-tumor T-cell activity and myeloid cell activation, which are crucial for the immune system's ability to effectively combat cancer. PD-1 is known to suppress T-cell activity when bound to its ligands, while TIM-3 is involved in T-cell exhaustion and immune evasion by tumors. By simultaneously blocking both of these pathways, Sabestomig aims to enhance anti-tumor immune responses and overcome resistance to current immunotherapies.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The development of Sabestomig is based on the hypothesis that dual inhibition of PD-1 and TIM-3 can overcome the immune resistance seen in some cancer patients. Resistance to immunotherapies such as PD-1/PD-L1 inhibitors is a significant challenge in oncology, and Sabestomig offers a novel approach to address this issue. By targeting two immune checkpoints that regulate T-cell function and myeloid activation, Sabestomig may restore the immune system’s ability to recognize and attack tumor cells more effectively. Preclinical and early clinical data have shown that Sabestomig can overcome resistance to PD-1 inhibitors, making it a promising candidate for combination therapies.
Currently, Sabestomig is being evaluated in Phase 2 clinical trials for patients with locally advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma. These trials are investigating the efficacy of Sabestomig in combination with chemotherapy, with the goal of improving clinical outcomes for patients who may not respond adequately to standard treatments. If successful, Sabestomig could offer a new strategy to enhance the effectiveness of immunotherapy in a range of solid tumors, particularly those that have been resistant to other checkpoint inhibitors.